Posts by LMK Clinical Research Consulting

Come meet LMK at booth 823 at DIA! We think it’s fitting that an event that will shape the future of the pharmaceutical industry is held in a city that is both entrenched in the history of our country and fully committed to the innovations of the future. Although LMK isn’t local to Boston, we…

A Message from Sholeh Ehdaivand President and CEO of LMK Clinical Research Consulting Sometimes when we are watching TV together, and an ad for a new drug comes on screen, my kids will ask, ‘Mom did you work on that?’ Sometimes I can say, yes I did! My first step as an entrepreneur was made…

In anticipation of the release of version 3 of the TMF Reference Model and in honor of David Letterman’s last “Late Show” appearance, this post mimics his famous Top 10 list. Here are the Top 10 reasons to implement the TMF Reference Model. Enjoy! #10. You can finally answer the question “does this document belong…

Great Britain’s MHRA (Medicines and Healthcare products Regulatory Agency) is known (and feared) for their high expectations regarding the TMF. MHRA expects your TMF to be “the story of how the trial was conducted and managed.” Their “inspectors want to reconstruct the trial conduct so that it can be evaluated for compliance …[and] review any…

“No-one goes to work to do a bad job!” This quote, penned by legendary management thinker W. Edwards Deming, was introduced to us by a friend of LMK, process improvement and human factors guru, Keith Dorricott. In a recent LMK webinar, Keith discussed best practices for TMF metrics, and arrived at the conclusion that this…

Is your TMF ready for GDPR? This is the third and final post of a series examining how the new European Union General Data Protection Regulation could affect your trial master file. See part one and part two which examine the basic roles within GDPR and the foundational rights of data subjects. Serious Penalties and…